Person:
Borges, Christopher M.

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Borges

First Name

Christopher M.

Name

Borges, Christopher M.

Filters

2014 - 20152

Settings

Author's Publications: search.filters.isAuthorOfPublication.b04ccbbc-b70f-4ce4-9123-0bc6f5a0d822

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    The phosphatase PTEN-mediated control of PI-3 kinase in Tregs cells maintains homeostasis and lineage stability
    (2014) Huynh, Alexandria; DuPage, Michel; Priyadharshini, Bhavana; Sage, Peter; Quiros, Jason; Borges, Christopher M.; Townamchai, Natavudh; Gerriets, Valerie A.; Rathmell, Jeffrey C.; Sharpe, Arlene; Bluestone, Jeffrey A.; Turka, Laurence
    Foxp3+ regulatory T cells (Tregs) are required for immune homeostasis. One notable distinction between conventional T cells (Tconv) and Tregs is differential phosphatidylinositol 3-kinase (PI3K) activity: only Tconv downregulate PTEN, the primary negative regulator of PI3K, upon activation. Here, we show that control of PI3K in Tregs is essential for lineage homeostasis and stability. Mice lacking Pten in Tregs developed an autoimmune-lymphoproliferative disease characterized by excessive TH1 responses and B cell activation. Diminished control of PI3K activity in Tregs led to reduced CD25 expression, accumulation of Foxp3+CD25− cells and ultimately, loss of Foxp3 expression in these cells. Collectively, these data demonstrate that control of PI3K signaling by PTEN in Tregs is critical to maintain their homeostasis, function and stability.
  • No Thumbnail Available
    Publication
    Defining a Role for T Regulatory Cell Expressed MyD88 During the Response to Allografts
    (2015-11-16) Borges, Christopher M.; Sharpe, Arlene; Turka, Laurence; Moon, James; Robson, Simon; Harris, John
    The myeloid differentiation primary response gene 88 (MyD88) is an adaptor protein proximally downstream of the Toll-like receptor (TLRs) and the IL-1 receptor family (IL-1R, IL- 18R and IL-33R). The TLR-MyD88 signaling pathway enables the innate immune system to sense inflammation and promote adaptive immune responses. TLRs are also expressed on T cells, and we have previously demonstrated that T cell intrinsic MyD88 signaling promotes T cell survival and is required for optimal responses to pathogens such as T. gondii and LCMV. Surprisingly however, we observed that mice with a targeted T cell deletion of MyD88 (MyD88fl/fl x CD4-Cre, termed MyD88-ΔT) reject bm12 cardiac allografts, and bm12 skin allografts when treated with αCD154 and rapamycin, at a higher frequency than wild type (WT) mice. As Tregs are critical for graft prolongation following costimulatory blockade in this model, we hypothesized a “defect” in MyD88-ΔT Tregs in the above model. As MyD88-ΔT mice do not allow us to differentiate the effect of MyD88 deletion specifically on Tregs versus the T cell compartment as a whole, we created mice with a targeted deletion of MyD88 specific to Tregs (MyD88fl/fl x FoxP3-Cre-YFP, MyD88-ΔTreg). MyD88-ΔTreg mice, similar to MyD88-ΔT mice have a similar Treg frequency when compared to WT mice and have no observable signs of autoimmunity. We found that MyD88-ΔTreg mice failed to accept bm12 skin allografts at the same frequency as WT control mice when given CoB, suggesting that the phenotype we observed in the MyD88-ΔT mice was likely caused by MyD88 deficient Tregs. As T cell intrinsic MyD88 is required for T cell survival during the response to pathogens, we thus hypothesized that the inability for MyD88 deficient Tregs to promote long-term allograft survival was due to an inability of these cells to survive. Surprisingly, through a series of in vivo and in vitro experiments, we observed that MyD88 deficient Tregs survive as well as WT Tregs under competitive conditions with WT Tregs, during activation with αCD3 and αCD28, as well as in the allograft 21 days post transplantation. In addition, MyD88 deficient Tregs survived as well as WT Tregs when activated and cultured with rapamycin and αCD154. In an attempt to reconcile the inability of MyD88-deficient Tregs to promote graft survival with their surprising ability to survive as well as WT Tregs, we next assessed the function of MyD88-deficient Tregs. In an in vitro suppression assay, MyD88-deficient Tregs suppressed effector T cell proliferation as well as WT Tregs at multiple Treg:T effector ratios. In addition, MyD88-deficient Tregs expressed similar levels of the Treg functional proteins CTLA-4, PD-1, Granzyme B, Lag-3, GITR, CD39, CD73 and CD28 as WT Tregs, suggesting that the function of MyD88-deficient Tregs may only be impaired during the response to alloantigen. Together, these data define MyD88 as having a divergent requirement for cell survival in non-Tregs and Tregs, and a yet-to-be defined functional requirement in Tregs during the response to alloantigen.